PureTech Health PLC
NASDAQ:PRTC

Watchlist Manager
PureTech Health PLC Logo
PureTech Health PLC
NASDAQ:PRTC
Watchlist
Price: 19.2125 USD 0.22%
Market Cap: 459.8m USD

Operating Margin

-24.7%
Current
Improving
by 61.8%
vs 3-y average of -86.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-24.7%
=
Operating Income
$-117.6m
/
Revenue
$6.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-24.7%
=
Operating Income
$-117.6m
/
Revenue
$6.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
PureTech Health PLC
LSE:PRTC
314.3m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
40.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 78% of companies in the United States of America
Percentile
22nd
Based on 14 112 companies
22nd percentile
-24.7%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

PureTech Health PLC
Glance View

Market Cap
459.8m USD
Industry
Biotechnology

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.

PRTC Intrinsic Value
2.2865 USD
Overvaluation 88%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-24.7%
=
Operating Income
$-117.6m
/
Revenue
$6.4m
What is PureTech Health PLC's current Operating Margin?

The current Operating Margin for PureTech Health PLC is -24.7%, which is above its 3-year median of -86.6%.

How has Operating Margin changed over time?

Over the last 3 years, PureTech Health PLC’s Operating Margin has decreased from -12% to -24.7%. During this period, it reached a low of -368.8% on Jun 30, 2024 and a high of -12% on Jun 30, 2022.

Back to Top